Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Angelo M. De Marzo"'
Autor:
Adrianna A. Mendes, Jiayun Lu, Harsimar B. Kaur, Siqun L. Zheng, Jianfeng Xu, Jessica Hicks, Adam B. Weiner, Edward M. Schaeffer, Ashley E. Ross, Steven P. Balk, Mary‐Ellen Taplin, Nathan A. Lack, Emirhan Tekoglu, Janielle P. Maynard, Angelo M. De Marzo, Emmanuel S. Antonarakis, Karen S. Sfanos, Corinne E. Joshu, Eugene Shenderov, Tamara L. Lotan
Publikováno v:
Cancer
Background: B7 homolog 3 (B7-H3) is an immunomodulatory molecule that is highly expressed in prostate cancer (PCa) and belongs to the B7 superfamily, which includes PD-L1. Immunotherapies (antibodies, antibody-drug conjugates, and chimeric antigen re
Autor:
Srinivasan Yegnasubramanian, Janis M. Taube, Angelo M. De Marzo, Busra Ozbek, Carolina Gomes Alexandre, Onur Ertunc, Tracy Jones, Andrew Erickson, Jessica L. Hicks, Karen S. Sfanos, Gunes Guner, Igor Vidal
Background Most prostate cancers are "immune cold" and poorly responsive to immune checkpoint inhibitors. However, the mechanisms responsible for the lack of a robust antitumor adaptive immune response in the prostate are poorly understood, which hin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c591f71687247183a020de67df431d23
http://acikerisim.sdu.edu.tr/xmlui/handle/123456789/96552
http://acikerisim.sdu.edu.tr/xmlui/handle/123456789/96552
Autor:
Susan L. Dalrymple, Yezi Zhu, Peter S. Nelson, Jun Luo, Jianfeng Xu, Alan K. Meeker, Samuel R. Denmeade, Emmanuel S. Antonarakis, S. Lilly Zheng, William B. Isaacs, Angelo M. De Marzo, Jody E. Hooper, Ilsa Coleman, John T. Isaacs, W. Nathaniel Brennen
Publikováno v:
Oncogene
The role of truncated androgen receptor splice variant-7 (AR-V7) in prostate cancer biology is an unresolved question. Is it simply a marker of resistance to 2nd-generation androgen receptor signaling inhibitors (ARSi) like abiraterone acetate (Abi)
Autor:
David Lim, Mindy K. Graham, Eva Corey, Tamara L. Lotan, Jonathan I. Epstein, Alan K. Meeker, Christopher M. Heaphy, Hao Wang, Mario A. Eisenberger, Angelo M. De Marzo, Christine Davis, Michael C. Haffner
Publikováno v:
Hum Pathol
BACKGROUND: Small cell neuroendocrine carcinoma (SCNC) of the prostate is an aggressive subtype with frequent TP53 mutation and RB1 inactivation, however the molecular phenotype remains an area of investigation. Here, we compared telomere lengths in
Autor:
Ibrahim Kulac, Heidi Hempel Sullivan, Nathan Cuka, John R. Barber, Christopher M. Heaphy, Angelo M. De Marzo, Jiayun Lu, Tamara L. Lotan, Corinne E. Joshu, Karen S. Sfanos
Publikováno v:
Cancer Epidemiology, Biomarkers & Prevention. 29:668-675
Background: Given our previous findings that low intratumoral and high extratumoral mast cell numbers are associated with higher risk of biochemical recurrence after radical prostatectomy, we now assessed this relationship with race and the developme
Autor:
Jessica L. Hicks, Tamara L. Lotan, Angelo M. De Marzo, Ayanna M Carter, Lauren B. Peiffer, Luke Mummert, Rebecca Y Sosa, Jiayun Lu, Corinne E. Joshu, Karen S. Sfanos, Ryan Kempski, Igor Vidal, Tamirat Ali, Janielle P. Maynard
Publikováno v:
J Pathol
Prostate cancer (PCa) remains a leading cause of cancer-related deaths in American men and treatment options for metastatic PCa are limited. There is a critical need to identify new mechanisms that contribute to PCa progression, that distinguish beni
Autor:
Todd Cohen, Misop Han, Igor Vidal, Bruce J. Trock, Stephanie Glavaris, Alan W. Partin, Angelo M. De Marzo, Brent Mabey, Steven Stone, Tracy Jones
Publikováno v:
Journal of Urology. 206
INTRODUCTION AND OBJECTIVE:The cell cycle progression (CCP) score and PTEN have never been evaluated together for metastasis-free survival (MFS) in a prostatectomy (RP) cohort of men with intermedi...
Autor:
Radhika A. Patel, Lizamma Antony, Roshan Chikarmane, William G. Nelson, Jun Luo, Ilsa Coleman, Michael C. Haffner, Angelo M. De Marzo, Eva Corey, S. Lilly Zheng, Peter S. Nelson, Jody E. Hooper, Srinivasan Yegnasubramanian, John T. Isaacs, Alan K. Meeker, W. Nathaniel Brennen, Jianfeng Xu, William B. Isaacs, Brian Hanratty, Susan L. Dalrymple, Yezi Zhu
Publikováno v:
JCI Insight, Vol 6, Iss 8 (2021)
JCI Insight
JCI Insight
Resistance to AR signaling inhibitors (ARSis) in a subset of metastatic castration-resistant prostate cancers (mCRPCs) occurs with the emergence of AR- neuroendocrine prostate cancer (NEPC) coupled with mutations/deletions in PTEN, TP53, and RB1 and
Autor:
Angelo M. De Marzo, Jeffrey J. Tosoian, Tamara L. Lotan, Ashley E. Ross, Mufaddal Mamawala, Liana B. Guedes, H. Ballentine Carter, Bruce J. Trock, Misop Han, Carlos L. Morais
Publikováno v:
Prostate cancer and prostatic diseases
Background: Up to half of men with Gleason score 6 (GS6) prostate cancers initially managed with active surveillance (AS) will eventually require definitive therapy, usually due to tumor grade reclassification during follow-up. We examined the associ
Autor:
Charles J. Bieberich, Angelo M. De Marzo, Srinivasan Yegnasubramanian, David M. Esopi, Qizhi Zheng, Gretchen K. Hubbard, Apurv Rege, Jessica Hicks, Mark C. Markowski, Alexia King
Publikováno v:
Prostate
Background Loss or mutation of PTEN alleles at 10q23 in combination with 8q24 amplification (encompassing MYC) are common findings in aggressive, human prostate cancer. Our group recently developed a transgenic murine model of prostate cancer involvi